Epstein Secrets

ynthetic Cannabinoids Screen (2019 Scope), Blood - Femoral Blood -Analysis by High Performance Liquid Chromatography/Tandem Mass Spectrometry QTRAP (LC-MS/MS QTRAP) for. Compound 4-cyano-CUMYL-BINACA 0.10 ng/mL AMB-FUBINACA 1.0 ng/mL 4-fluoro-MDMB-BINACA 0.10 ng/mL CUMYL-THPINACA 0.10 ng/mL 5

e preliminary autopsy results. It is requested that the assigned ME discuss the preliminary autopsy findings with FBI Special Agent Disposition: ME Case/Hospital with MLI Scene Investigation. NOK Does Not Object to Autopsy. NOK Plans to Retain an Independent Forensic Pathologist to Observe Autopsy. The info

ynthetic Cannabinotds Screen (2019 Scope), Blood - Femoral Blood -Analysis by High Performance Liquid Chromatography/Tandem Mass Spectrometry QTRAP (LC-MS/MS QTRAP) for aaranstuad Ret Limit COOMBS' Rot—Limit 4-cyano-CUMYL-BINACA 0.10 ng/mL AMB-FUBINACA 1.0 ng/mL 4-fluoro-MDMB-BINACA 0.10 ng/m

e preliminary autopsy results. It is requested that the assigned ME discuss the preliminary autopsy findings with FBI Special Agent Disposition: ME Case/Hospital with MLI Scene Investigation. NOK Does Not Object to Autopsy. NOK Plans to Retain an Independent Forensic Pathologist to Observe Autopsy. The info

ynthetic Cannabinoids Screen (2019 Scope), Blood - Femoral Blood -Analysis by High Performance Liquid Chromatography/Tandem Mass Spectrometry QTRAP (LC-MS/MS QTRAP) for Compound Rid I iat C.00.12011XL Rot Limit 4-cyano-CUMYL-BINACA 0.10 ng/mL AMB-FUBINACA 1.0 ng/mL 4-fluoro-MDMB-BINACA 0.10 n

he preliminary autopsy results. It is requested that the assigned ME discuss thepreliminary autopsy findings with FBI Special Agent Disposition: ME Case/Hospital with MLI Scene Investigation. NOK Does Not Object to Autopsy. NOK Plans to Retain an Independent Forensic Pathologist to Observe Autopsy. The info